Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
HOPX Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application 
| WB, FC, E |
|---|---|
| Primary Accession | Q9BPY8 |
| Other Accession | NP_001138931.1, NP_631957.1, NP_115884.4 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 8260 Da |
| Antigen Region | 39-67 aa |
| Gene ID | 84525 |
|---|---|
| Other Names | Homeodomain-only protein, Lung cancer-associated Y protein, Not expressed in choriocarcinoma protein 1, Odd homeobox protein 1, HOPX, HOD, HOP, LAGY, NECC1, OB1 |
| Target/Specificity | This HOPX antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-67 amino acids from the C-terminal region of human HOPX. |
| Dilution | WB~~1:1000 FC~~1:10~50 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | HOPX Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | HOPX |
|---|---|
| Synonyms | HOD, HOP, LAGY, NECC1, OB1 |
| Function | Atypical homeodomain protein which does not bind DNA and is required to modulate cardiac growth and development. Acts via its interaction with SRF, thereby modulating the expression of SRF- dependent cardiac-specific genes and cardiac development. Prevents SRF- dependent transcription either by inhibiting SRF binding to DNA or by recruiting histone deacetylase (HDAC) proteins that prevent transcription by SRF. Overexpression causes cardiac hypertrophy (By similarity). May act as a tumor suppressor. Acts as a co-chaperone for HSPA1A and HSPA1B chaperone proteins and assists in chaperone-mediated protein refolding (PubMed:27708256). |
| Cellular Location | Nucleus {ECO:0000250|UniProtKB:Q8R1H0}. Cytoplasm {ECO:0000250|UniProtKB:Q8R1H0} |
| Tissue Location | Widely expressed. Expressed in the heart, brain, placenta, lung, skeletal and smooth muscles, uterus, urinary bladder, kidney and spleen. Down-regulated in some types of cancer such as lung cancer, choriocarcinoma, head and neck squamous cell carcinoma and oral squamous cell carcinoma. |
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a homeodomain protein that lacks certain conserved residues required for DNA binding. It was reported that choriocarcinoma cell lines and tissues failed to express this gene, which suggested the possible involvement of this gene in malignant conversion of placental trophoblasts. Studies in mice suggest that this protein may interact with serum response factor (SRF) and modulate SRF-dependent cardiac-specific gene expression and cardiac development. Multiple alternatively spliced transcript variants have been identified for this gene. [provided by RefSeq].
References
Yang, J.M., et al. Eur. J. Cell Biol. 89(7):537-546(2010)
Ooki, A., et al. Oncogene 29(22):3263-3275(2010)
Yamaguchi, S., et al. Int. J. Cancer 124(11):2577-2588(2009)
Yamashita, K., et al. Mol. Cancer Res. 6(1):31-41(2008)
De Toni, A., et al. Neural Dev 3, 13 (2008) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
